Hemlibra to be available nationally
Tue 29 Sep 2020
We are delighted that the Federal Minister for Health, The Hon. Greg Hunt MP, announced on Saturday 26 September 2020 that emicizumab (Hemlibra®) will be publicly funded as a treatment for Australians with haemophilia
Hemlibra® is a treatment that can reduce or stop bleeding in people with severe or moderate haemophiia A with and without inhibitors.
Gavin Finkelstein, HFA President, said, 'this is great news for our community. We are pleased all governments in Australia have agreed to fund their share of the costs of this treatment product for those in our community who need it'.
The National Blood Authority (NBA) has released information about the arrangements to add emicizumab (Hemlibra®) as a treatment for Australians along with the other treatments for bleeding disorders on the National Product List.
Adding Hemlibra to the National Product List means that there will be consistent access to the treatment around Australia.
The National Blood Authority said, ‘Hemlibra will be prescribed by a specialist clinician in a recognised Haemophilia Treatment Centre, which will continue to provide coordinated access consistent with the current framework for access to therapies for haemophilia.’
Supply of Hemlibra under NBA arrangements is expected to commence by December 2020.
More information about access and transition arrangements is available on the National Blood Authority website - National supply arrangements for Hemlibra
Last Reviewed: 29 September 2020
Date last reviewed: 29 September 2020
Search News by Category